New treatment targets BRAFV600E-mutant mCRC after prior therapy

Targeting G-quadruplexes may restore chemotherapy effectiveness

New regulations aim to simplify processes and strengthen patient safety

OVX836 shown to be safe and effective alongside seasonal Fluarix Tetra

BX004 achieves 500-fold bacterial reduction with no resistance in phase 1b/2a study

Funding to support lead candidate targeting FAP and pipeline expansion

New trial to test VMX-C001’s effectiveness in restoring coagulation in FXa DOAC patients

Enter the 2025 PharmaTimes Clinical Researcher of the Year – The Americas

PulseSight begins phase 1 safety study of gene therapy for geographic atrophy

SMC approval provides option for postmenopausal women at risk of fractures